Lawsuits concerning Bayer’s Yaz and Yasmin birth control products continue to mount as more women come forward after having suffered strokes, heart attacks, pulmonary emboli, and gall bladder problems as a result of taking the birth control. The lawsuits have been consolidated in a multi district litigation in U.S. District Court for the Southern District of Illinois. Thus far, there have been approximately 300 such lawsuits filed across the country.
Both Yaz and Yasmin are manufactured by Bayer Pharmaceuticals containing a combination of ethinyl estradiol and drospirenone, a new type of progestin. Drospirenone, or drsp, impacts the body’s normal mechanism of regulating a balance between salt and water, which could result in elevated potassium levels. The unique progestin has been implicated as the likely cause of the
issues surrounding both Yaz and Yasmin.
According to an August 2009 study published in the British Medical Journal, the drospirenone contained in Yaz and Yasmin carry 6.3 times increased risk of developing blood clots, deep vein thrombosis, or pulmonary embolism than other forms of birth control.
- Federal Judge Finds Health Insurer DiscriminatedAgainst Patients with Substance Abuse and Mental Health Disorders - March 25, 2019
- Factors Impacting Maternal Health During Hospital Births - March 22, 2019
- Jury Awards $117 million in Johnson & Johnson’sFirst Trial Loss in Asbestos-Related, Talc Powder Lawsuits - April 24, 2018